AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn’s Disease

AbbVie Inc. (NYSE:ABBV) is 1 of the champion undervalued stocks to put successful close now.

AbbVie Inc. (NYSE:ABBV) announced connected March 2 affirmative topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM survey evaluating the efficacy and information of risankizumab subcutaneous induction attraction versus placebo successful big patients with moderately to severely progressive Crohn's disease. The institution reported that results from the survey amusement notably higher proportions of patients treated with risankizumab SC induction attained the co-primary endpoints of Crohn's Disease Activity Index objective remission and endoscopic effect astatine week 12 compared to placebo.

Kori Wallace, M.D., Ph.D., vice president, planetary caput of immunology objective development, AbbVie Inc. (NYSE:ABBV), stated that the level of endoscopic effect marks a peculiarly meaningful accomplishment for Crohn's illness patients, and that these results item the company’s continued innovation and probe to rise the modular of care.

The institution further reported that during the 12-week, double-blind, placebo-controlled period, the information illustration of risankizumab SC remained accordant with the information illustration observed successful Crohn's disease, with nary caller information risks observed. Upper respiratory tract infection, abdominal pain, and arthralgia were the astir communal adverse events observed among patients receiving risankizumab, and superior adverse events occurred successful 0.5% of patients successful the risankizumab SC radical compared to 3.1% successful the placebo group.

AbbVie Inc. (NYSE:ABBV) is simply a research-based pharmaceutical institution that develops and sells products to dainty chronic diseases successful oncology, gastroenterology, rheumatology, dermatology, virology, and assorted different superior wellness conditions.

While we admit the imaginable of ABBV arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. Follow Insider Monkey connected Google News.